Unspecified menopausal and perimenopausal disorder
Methodology & AI Transparency ⓘ
Unspecified menopausal and perimenopausal disorder Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Unspecified menopausal and perimenopausal disorder is an ICD-10-CM indexed diagnosis (N95.9) within Menopause, Perimenopause & Hormone Therapy.
- 2 Real-world patient consensus: Federal ICD-10-CM code N95.9 categorizes Unspecified menopausal and perimenopausal disorder under Menopause, Perimenopause & Hormone Therapy.
- 3 Typical cash cost range: Primary evaluation for Unspecified menopausal and perimenopausal disorder incorporates STRAW+10 clinical staging [Unspecified menopausal and perimenopausal disorder N95.9] and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Unspecified menopausal and perimenopausal disorder monitoring tracks TSH & HbA1c in Unspecified menopausal and perimenopausal disorder (N95.9: Midlife Panel) toward TSH 0.8–2.5 mIU/L; HbA1c < 5.6% (N95.9).
Ask our AI Specialists anything about Unspecified menopausal and perimenopausal disorder
What Is Unspecified menopausal and perimenopausal disorder?
Unspecified menopausal and perimenopausal disorder is an ICD-10-CM indexed diagnosis (N95.9) within Menopause, Perimenopause & Hormone Therapy. Clinical evaluation centers on STRAW+10 clinical staging [Unspecified menopausal and perimenopausal disorder N95.9] alongside serial TSH & HbA1c in Unspecified menopausal and perimenopausal disorder (N95.9: Midlife Panel) tracking (TSH 0.8–2.5 mIU/L; HbA1c < 5.6% (N95.9)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Unspecified menopausal and perimenopausal disorder (N95.9) center on declining ovarian follicular in Unspecified menopausal and perimenopausal disorder (N95.9: reserve with fluctuating). targeted menopause & hrt interventions aim to normalize TSH & HbA1c in Unspecified menopausal and perimenopausal disorder (N95.9: Midlife Panel).
Common Symptoms & Clinical Signs
- • Presentation of Unspecified menopausal and perimenopausal disorder (N95.9): vasomotor hot flashes, in Unspecified menopausal and perimenopausal disorder (N95.9: sudden facial/chest warmth,)
- • Secondary Unspecified menopausal and perimenopausal disorder clinical sign: new-onset 3 AM in Unspecified menopausal and perimenopausal disorder (N95.9: sleep disruption, brain)
- • Symptom flares in Unspecified menopausal and perimenopausal disorder correlating with TSH & HbA1c in Unspecified menopausal and perimenopausal disorder (N95.9: Midlife Panel) deviation outside TSH 0.8–2.5 mIU/L; HbA1c < 5.6% (N95.9)
- • Functional menopause & hrt impact requiring STRAW+10 clinical staging [Unspecified menopausal and perimenopausal disorder N95.9] evaluation (N95.9)
Unspecified menopausal and perimenopausal disorder Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N95.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Menopause, Perimenopause & Hormone Therapy | NLM Clinical Tables |
| Diagnostic / Lab Marker: TSH & HbA1c in Unspecified menopausal and perimenopausal disorder (N95.9: Midlife Panel) | TSH 0.8–2.5 mIU/L; HbA1c < 5.6% (N95.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 17-Beta Estradiol & in Unspecified menopausal and perimenopausal disorder (N95.9: FSH (Contextual)) | Symptom-guided physiological target (N95.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: DEXA Bone Density in Unspecified menopausal and perimenopausal disorder (N95.9: & Fasting ApoB) | T-Score > -1.0; ApoB < 75 mg/dL (N95.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Unspecified menopausal and perimenopausal disorder
Treatment selection for Unspecified menopausal and perimenopausal disorder depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Unspecified menopausal and perimenopausal disorder)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Estradiol and progesterone bioavailability for moderate to severe vasomotor: What a 1,835-Participant Study Found P4 levels observed with TX-001HR were similar in the phase 1 and 3 studies, and were associated with no endometrial hyperplasia with either E2 daily dose over 1 year in the REPLENISH phase 3 study, which showed significant... Menopause (New York, N.Y.) • 2019-07-15 • Phase III Randomized Trial | N = 1,835 | 96/100 | PMID 30694918 ↗ |
| New Insights on Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral: What a 1,835-Participant Study Found All doses of TX-001HR provided endometrial protection and were associated with an improved bleeding profile over time; older age, further last menstrual period, or lower baseline E2 may predict amenorrhea with TX-001HR. Menopause (New York, N.Y.) • 2020-04-15 • Phase III Randomized Trial | N = 1,835 | 96/100 | PMID 31913228 ↗ |
| New Insights on Psychometric evaluation of the HFDD, PROMIS SD SF 8b, and MENQOL questionnaire in: What a 400-Participant Study Found Findings provide evidence that HFDD, PROMIS SD SF 8b, and MENQOL scores are valid, reliable and responsive to change, supporting their use for assessing key efficacy endpoints in VMS clinical trials. Journal of patient-reported outcomes • 2025-05-07 • Phase III Randomized Trial | N = 400 | 93/100 | PMID 40332718 ↗ |
| New Insights on Low-dose and ultra-low-dose estradiol and dydrogesterone in postmenopause: an: What a 640-Participant Study Found Oral, ultra-low-dose continuous combined E0.5 mg/D2.5 mg and low-dose continuous combined E1 mg/D5 mg alleviated postmenopausal VMS compared with placebo, irrespective of BMI. Climacteric : the journal of the International Menopause Society • 2025-02-15 • Phase III Randomized Trial | N = 640 | 93/100 | PMID 39475406 ↗ |
| New Insights on Ultra-low-dose estradiol and dydrogesterone for treatment of vasomotor symptoms: What a 288-Participant Study Found Oral, ultra-low-dose continuous combined 0.5 mg 17β-estradiol and 2.5 mg dydrogesterone improved VMS compared with placebo in European and Chinese postmenopausal women, with a positive impact on health-related quality of life. Climacteric : the journal of the International Menopause Society • 2024-10-15 • Phase III Randomized Trial | N = 288 | 93/100 | PMID 39077780 ↗ |
Unspecified menopausal and perimenopausal disorder Patient Community & “People Like Me” Threads
Filter Unspecified menopausal and perimenopausal disorder community threads and patient logs by age, biological sex, dosage, and treatment duration.